Neurocrine Biosciences (NBIX) : The highest short term price target forecast on Neurocrine Biosciences (NBIX) is $96 and the lowest target price is $57. A total of 8 equity analysts are currently covering the company. The average price of all the analysts is $70 with a standard deviation of $13.05.
Also, H.C. Wainwright initiates coverage on Neurocrine Biosciences (NASDAQ:NBIX) In a research note issued to the investors, the brokerage major announces price-target of $80 per share.The shares have been rated Buy. The rating by the firm was issued on June 29, 2016.
Neurocrine Biosciences (NASDAQ:NBIX): During Thursdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $48.63 and $48.35 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $50.28. The buying momentum continued till the end and the stock did not give up its gains. It closed at $50.12, notching a gain of 3.43% for the day. The total traded volume was 568,942 . The stock had closed at $48.46 on the previous day.
Neurocrine Biosciences, Inc. is engaged in the development of pharmaceutical products focused on neurological and endocrine based diseases and disorders. The Companys two lead late-stage clinical programs are elagolix, a gonadotropin releasing hormone (GnRH) antagonist for womens health that is partnered with AbbVie Inc. (AbbVie), and a vesicular monoamine transporter 2 (VMAT2) inhibitor for the treatment of movement disorders. elagolix is in clinical trials for the treatment of Endometriosis and Uterine Fibroids. VMAT2 (NBI-98854) is a VMAT2 inhibitor in clinical trials for the treatment of tardive dyskinesia. Corticotropin-Releasing Factor (CRF) receptor antagonist (NBI-77860) is indicated for the treatment of Classic Congenital Adrenal Hyperplasia. NBI-77860 is a selective, orally-active, non-peptide CRF receptor antagonist.